Scale of R&D Personnel and Expenditure
First written in FY2016. 14 of 35 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Other".
- FY2026Year-to-date R&D expenses down year on yearAnnual report
「R&D expenses for the fiscal year decreased by ¥400 million from the previous fiscal year to ¥25,600 million, down 1.4% year on year.」
In terms of the scale of R&D resources, R&D expenses were ¥25.6 billion, down 1.4% year on year. - FY2026-H1Year-on-year decline in first-half R&D expensesAnnual report
「The Group's total R&D expenditures for the interim consolidated accounting period were ¥13.130 billion.」
First-half R&D expenses were ¥13.130 billion, down from ¥13.244 billion in the same period of the previous year. R&D activities themselves have continued. - FY2025-H1Year-on-year increase in first-half R&D expenditureAnnual report
「The Group's total R&D expenditures for the interim consolidated accounting period were ¥13.244 billion.」
First-half R&D expenses were ¥13.244 billion, up from ¥11.457 billion in the same period of the previous year. - FY2024Year-on-year increase in annual R&D expenditureAnnual report
「R&D expenditure for the fiscal year was ¥23.4 billion, up ¥1.5 billion from the previous consolidated fiscal year, a 6.9% year-on-year increase.」
R&D expenses were ¥23.4 billion, up 6.9% year on year. - FY2024-Q3Year-on-year increase in third-quarter R&D expenditureAnnual report
「Group-wide R&D expenditure for the first nine months of the current consolidated cumulative period was ¥17.938 billion.」
R&D expenditure for the first nine months was ¥17.938 billion, up from ¥16.716 billion in the same period of the previous year. - FY2024-Q2Year-on-year increase in first-half R&D expenditureAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥12.148 billion.」
First-half R&D expenditure was ¥12.148 billion, up from ¥11.457 billion in the same period of the previous year. - FY2024-Q1Year-on-year increase in quarterly R&D expenditureAnnual report
「Group-wide R&D expenditure for the fiscal year was ¥6.374 billion.」
First-quarter cumulative R&D expenditure was ¥6.374 billion, up from ¥5.844 billion in the same period of the previous year. - FY2023Year-on-year increase in annual R&D expenditureAnnual report
「R&D expenditure for the fiscal year was ¥21.9 billion, up ¥1.1 billion from the previous consolidated fiscal year, a 5.5% year-on-year increase.」
R&D expenditure was ¥21.9 billion, up 5.5% year on year. - FY2023-Q3Year-on-year increase in third-quarter R&D expenditureAnnual report
「Group-wide R&D expenditure for the first nine months of the current consolidated cumulative period was ¥16.716 billion.」
R&D expenditure for the first nine months was ¥16.716 billion, up from ¥15.604 billion in the same period of the previous year. - FY2023-Q2Year-on-year increase in first-half R&D expenditureAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥11.457 billion.」
First-half R&D expenditure was ¥11.457 billion, up from ¥10.562 billion in the same period of the previous year. - FY2022AdvancedAnnual report
「R&D expenditure for the fiscal year was ¥20.7 billion, up ¥1.2 billion from the previous consolidated fiscal year, a 6.2% year-on-year increase.」
R&D expenditure was ¥20.7 billion, up 6.2% year on year. - FY2022-Q3Year-on-year increase in third-quarter R&D expenditureAnnual report
「Group-wide R&D expenditure for the first nine months of the current consolidated cumulative period was ¥15.604 billion.」
R&D expenditure for the first nine months was ¥15.604 billion, up from ¥14.608 billion in the same period of the previous year. - FY2022-Q2Slight year-on-year decline in first-half R&D expenditureAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥10.562 billion.」
First-half R&D expenditure was ¥10.562 billion, a slight decrease from ¥10.585 billion in the same period of the previous year. Continued resource allocation to R&D is taking place. - FY2022-Q1Year-on-year increase in quarterly R&D expenditureAnnual report
「Group-wide R&D activity expenses for the three-month period ended 30 June were ¥5,394 million.」
First-quarter cumulative R&D expenditure was ¥5.394 billion, up from ¥5.19 billion in the same period of the previous year. - FY2021Year-to-date R&D expenses down year on yearAnnual report
「R&D expenditure for the fiscal year was ¥19.5 billion, down ¥1.8 billion from the previous consolidated fiscal year, a decrease of 8.2% year on year.」
R&D expenditure was ¥19.5 billion, down 8.2% from ¥21.295 billion in the previous fiscal year. Meanwhile, R&D centered on SBUs, R&D and Proactive IP has continued. - FY2021-Q3Year-on-year decline in third-quarter R&D expenditureAnnual report
「Group-wide R&D expenditure for the first nine months of the current consolidated cumulative period was ¥14.608 billion.」
R&D expenditure for the first nine months was ¥14.608 billion, down from ¥16.007 billion in the same period of the previous year. - FY2021-Q2Decline in first-half research and development expensesAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥9.677 billion.」
First-half R&D expenditure was ¥9.677 billion, down from ¥10.585 billion in the same period of the previous year. Resource allocation to R&D itself has continued. - FY2021-Q1Quarterly R&D expenses decreasedAnnual report
「Group-wide R&D expenditure for the first quarter of the current consolidated cumulative period was ¥4.7 billion.」
R&D expenditure of ¥4.7 billion was disclosed. Although this was down from ¥5.19 billion in the same period of the previous year, it indicates continued resource allocation to R&D. - FY2020AdvancedAnnual report
「The Group has 1,376 R&D staff, representing 12% of total employees. Group-wide R&D expenditure for the fiscal year was ¥21.295 billion.」
R&D staff totaled 1,376, representing 12% of total employees, and R&D expenditure was ¥21.295 billion, expanding in scale from the previous fiscal year. - FY2020-Q3RestatedAnnual report
「Group-wide R&D expenditure for the first nine months of the current consolidated cumulative period was ¥16.007 billion.」
R&D expenditure of ¥16.007 billion for the first nine months was disclosed, reaffirming continued resource allocation to R&D. - FY2020-Q2RestatedAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥10.585 billion.」
R&D expenditure of ¥10.585 billion for the first half was disclosed, reaffirming continued resource allocation to R&D. - FY2020-Q1RestatedAnnual report
「Group-wide R&D activity expenses for the three-month period ended 30 June were ¥5,190 million.」
As part of its continued resource allocation to R&D, the Group disclosed first-quarter cumulative R&D expenditure of ¥5.19 billion. - FY2019AdvancedAnnual report
「The Group had 1,318 R&D personnel, representing 11% of total employees. Group-wide R&D expenses for the fiscal year were ¥20,749 million.」
R&D staff and R&D expenditure increased from 1,183 people and ¥18.843 billion, respectively, in the previous fiscal year, expanding the scale of R&D resources. - FY2019-Q3RestatedAnnual report
「Group-wide R&D activity expenses for the nine-month period ended 31 December were ¥15,181 million.」
R&D expenditure of ¥15.181 billion for the first nine months was disclosed, reaffirming continued resource allocation to R&D. - FY2019-Q2RestatedAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥9.969 billion.」
R&D expenditure of ¥9.969 billion for the first half was disclosed, reaffirming continued resource allocation to R&D. - FY2019-Q1RestatedAnnual report
「Group-wide R&D expenditure for the first quarter of the current consolidated cumulative period was ¥4.852 billion.」
R&D expenditure of ¥4.852 billion for the first quarter was disclosed, reaffirming continued resource allocation to R&D. - FY2018RestatedAnnual report
「The Group had 1,183 R&D personnel, representing 10% of total employees. Group-wide R&D expenses for the fiscal year were ¥18,843 million.」
The Group disclosed resource allocation consisting of 1,183 R&D staff, representing 10% of total employees, and R&D expenditure of ¥18.843 billion. - FY2018-Q3RestatedAnnual report
「The Group's total R&D activities amounted to ¥13.955 billion during the nine-month period ended in the third quarter.」
R&D expenditure of ¥13.955 billion for the first nine months was disclosed, indicating continued resource allocation to R&D. - FY2018-Q2RestatedAnnual report
「The Group's total R&D activities amounted to ¥905 million during the six-month period ended in the second quarter.」
R&D expenditure of ¥9.059 billion was disclosed, reaffirming continued resource allocation to R&D. - FY2018-Q1RestatedAnnual report
「Group-wide R&D expenditure for the first quarter of the current consolidated cumulative period was ¥4.574 billion.」
R&D expenditure of ¥4.574 billion for the first quarter was disclosed, indicating continued resource allocation to R&D. - FY2017RestatedAnnual report
「The Group has 1,128 R&D staff, representing 10% of total employees. Group-wide R&D expenditure for the fiscal year was ¥16.806 billion.」
The Group disclosed 1,128 R&D staff, representing 10% of total employees, and R&D expenditure of ¥16.806 billion, indicating continued resource allocation to R&D. - FY2017-Q3RestatedAnnual report
「Group-wide R&D expenditure for the first nine months of the current consolidated cumulative period was ¥12.2 billion.」
R&D expenditure of ¥12.2 billion was disclosed for the first nine months, indicating continued resource allocation to R&D. - FY2017-Q2RestatedAnnual report
「Group-wide R&D expenditure for the first half of the current consolidated cumulative period was ¥8.2 billion.」
R&D expenditure of ¥8.2 billion for the first half was disclosed, again indicating continued resource allocation to R&D. - FY2017-Q1RestatedAnnual report
「Group-wide R&D expenditure for the first quarter of the current consolidated cumulative period was ¥3.855 billion.」
R&D expenditure of ¥3.855 billion was disclosed for the quarter, indicating continued resource allocation to R&D. - FY2016First statedAnnual report
「The Group has 1,070 R&D staff, representing 10% of total employees. Group-wide R&D expenditure for the fiscal year was ¥15.306 billion.」
The resource allocation consists of R&D staff representing 10% of total employees and R&D expenditure of ¥15.306 billion.